【热点】培美替尼使胆管癌患者有了靶向疗法

The U.S. Food and Drug Administration (FDA) approved Incyte's latest targeted drug Pemazyre through the accelerated approval process on April 17, 2020, for the treatment of adults with advanced FCFR2 gene fusion cholangiocarcinoma that has been previously treated but has shown poor efficacy. The FDA adopted a priority review and approval process and granted it breakthrough therapy certification and orphan drug status. In addition, because pemetinib was approved through the accelerated approval process, developers should continue to conduct randomized controlled clinical trials and submit trial results. Pemetinib belongs to a class of drugs called kinase inhibitors. It works by blocking the action of abnormal proteins that signal cancer cells to multiply. This helps stop or slow the spread of cancer cells. The recommended dose is 13.5 mg orally daily for 14 days, followed by 7 days off in a 21-day cycle. Continue treatment until disease progression or unacceptable toxicity. Swallow the tablets whole, with or without food.

Pemetinib has not been approved for sale in China, and it has not yet been included in the national medical insurance to provide everyone with preferential policies. This means that patients will not be able to buy pemetinib at all in the country. Faced with this situation, more patients choose to go to distant overseas countries to purchase medicines under huge financial pressure. However, this method costs a lot of manpower, material resources and financial resources, which is miserable. However, according to Medical Companion Travel, the pemetinib version is very cost-effective and has been well received by many patients. The specification is 13.5mgx14 tablets and the price is about 341,175$. However, because the price of the drug rises and falls with the fluctuation of the exchange rate in the market, the specific price of the drug is not stable. For more information about pemetinib, please contact Medical Travel for details.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.